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ackground: Tramadol-diclofenac (TD-DF) could be used in chronic pain management. 
Concurrent use may present renal complications due to their individual nephrotoxic profile. The 
present study assessed the kidney function and histology of tramadol-diclofenac treated albino 
rats.  
Methods: Forty two adult albino rats divided into seven groups A-G were used for this study. Rats were 
orally administered with TD (12 mg/kg/day), DF (6 mg/kg/day), and TD-DF for 14 days including two 
recovery groups. Rats were weighed and sacrificed at the termination of drug treatment. Serum was 
extracted from blood and evaluated for creatinine (Cr), urea (U), uric acid (UA), total protein (TP), 
albumin (Ab) and serum electrolytes (K+, Na+, Cl-, and HCO3-). Kidneys were excised weighed and 
evaluated for alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase 
(AST), superoxide dismutase (SOD), catalase (CAT) glutathione (GSH), glutathione peroxidase (GPX), 
malondialdehyde (MDA) levels and histological damage. 
Results: The body weight, absolute and relative kidney weights and serum electrolytes were not 
significantly (p> 0.05) altered in the TD-DF treated rats in comparison to control. However, the levels of 
Cr, U, UA, AST, ALT, ALP and MDA were significantly (p<0.05) increased whereas Ab, TP, SOD, GSH, 
GPX and CAT were significantly (p<0.05) decreased in the TD-DF treated rats in comparison to 
treatments with individual doses of TD and DF. Varying degrees of histological damage were observed in 
the kidneys of TD-DF treated rats. However, nephrotoxic effects due to treatment with TD-DF were 
reversed in the recovery groups. 
Conclusion: The use of tramadol-diclofenac could be associated with reversible nephrotoxicity; therefore 
renal function assessment is advised before tramadol-diclofenac use. 
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Introduction  
In clinical practice, drugs are concurrently used in the 
treatment of severe and chronic pains that are 
irresponsive to monotherapy. In spite of the benefits 
expected from concurrent use of drugs there could be 
possible interactions that may lead to undesired or 
unexpected outcomes such as toxicities. In some 
instances the undesired or unexpected outcomes may 
outweigh the desired therapeutic benefits [1,2]. In the 
clinical assessment of possible toxicities that could arise 
as a product of drug interactions, some primary factors 
are taken into consideration. These factors include the 
patient age, duration of therapy, chemical nature of 
drugs, the number of drugs used and the status of the 
liver and kidney. The kidney is known to be one of the 
primary organs vulnerable to drug interactions which 
could impair its structure and functions. Kidney serves 
several, essential regulatory and excretory functions. 
These functions include maintenance of acid–base 
balance, electrolytes regulation, disposal of nitrogenous 
wastes, removal of drugs and their biotransformed 
products [3]. Also, it is responsible for the production of 
essential biochemical substances such as rennin, 
erythropoietin and calcitriol and the reabsorption of 
glucose, water, and amino acids [4].  
Kidney as the primary excretory organ for drugs, 
chemicals and biotransformed products is vulnerable to 
toxicity. This calls for its constant clinical assessment 
during therapy with drugs to safeguard it from toxicity 
[5]. 
Diclofenac (DF) has proven to be effective in the 
treatment of pain and is one of the commonly prescribed 
non steroidal anti-inflammatory drugs (NSAID). In 
addition to its analgesic effect, it has anti-inflammatory 
and antipyretic properties which make it suitable for the 
treatment of both peripheral and central pains. Studies 
have shown that its clinical benefit is due to the 
prevention of prostaglandin synthesis by inhibiting the 
activities of cyclooxygenase-1 and cyclooxygenase-2 [6]. 
However, the inhibition of renal prostaglandin synthesis 
by DF has been associated with nephrotoxicity. 
Reported nephrotoxicity with the use of DF could be 
characterized by alterations in renal biomarkers and 
kidney architecture [7,8]. Also, animal studies reported 
dose-dependent effects on kidney-linked stereological 
parameters such as renal damage, oxidative stress, 
plasma coagulation parameters and adenosine 
deaminase activity [9-11].  
Tramadol (TD) is an opioid analgesic that acts 
centrally; it has structural similarity with codeine and 
morphine. It is commonly and effectively used in the 
treatment of acute and chronic pains. Its beneficial effect 
is attributed to agonist action at the mu opioid receptor, 
and the inhibitory effect on norepinephrine and 
serotonin reuptake [12]. It has a good oral absorption; it 
is rapidly and almost completely absorbed and well 
distributed. TD and biotransformed products are 
excreted by the kidney via urine consequently; this 
makes the kidney a primary target organ of TD toxicity 
especially in cases of misuse and over dose. Some 
features of kidney damage associated with TD are 
cellular degeneration characterized by vacuolization, 
and tubular necrosis. Also, impaired levels of serum 
renal markers characterized by depletion of kidney 
antioxidant defence were features observed in animal 
studies [13]. 
Furthermore, because of failure of monotherapy, TD 
and DF could be used concurrently in the treatment of 
chronic pain. Concurrent use could be beneficial in 
ameliorating or abolishing both peripheral and central 
pains. Also, length of therapy could be reduced; 
analgesia could be produced at lower and more tolerable 
doses of the constituent drugs. Concurrent use could 
increase the ability of individual drugs to decrease pain, 
with increase tolerability and enhanced recovery time 
[14]. However, both drugs are known to be excreted by 
the kidney and are individually associated with 
nephrotoxicity. Therefore, concurrent use may 
precipitate drug interaction that may be characterized 
by nephrotoxic consequence which may lead to 
structural and functional changes in the kidney. 
However, in the absence of literature on the effect of 
diclofenac-tramadol on the kidney, this study assessed 
the renal effect of tramadol-diclofenac administration in 
albino rats.  
Methods 
Animals 
The rats used for this study were obtained from the 
animal house of the Faculty of Pharmacy, Niger Delta 
University, Wilberforce Island, Bayelsa State. The rats 
were housed as six per cage and had free access to food 
and water ad libitum. 
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Drugs 
Tramadol capsule used for this study was manufactured 
by Osaka Pharmaceutical India while diclofenac tablet 
was manufactured by Exus Pharmaceutical Nigeria. All 
other chemicals used are of analytical standard. 
Experimental protocol 
Forty two adult albino rats used for this study were 
divided into seven groups A-F with six rats in each 
group. Rats in groups A and B were treated with water 
and normal saline respectively as placebo and solvent 
control. Rats in groups C-E were treated with TD 
(12mg/kg/day), DF (6mg/kg/day) and TD-DF for 14 
days respectively. Rats in groups G and F (recovery 
groups) were treated with TD-DF orally for 14 days and 
allowed for 7 and 14 days wash-out periods respectively. 
The doses of tramadol and diclofenac used for this study 
represent 2 times maximum daily clinical doses. 
Collection of sample 
At the end of drug administration, rats were sacrificed 
using inhalational diethyl ether as anaesthesia.  Blood 
samples were collected, centrifuged at 1500 rpm for 20 
minutes and serum extracted and evaluated for renal 
function parameters. The kidneys were collected via 
dissection and washed in an ice cold 1.15% KCl solution. 
The kidneys were homogenized with 0.1M phosphate 
buffer (pH 7.2) and centrifuged at 1500 rpm for 20 
minutes. The supernatant was decanted and evaluated 
for oxidative stress indices and biochemical parameters.  
Evaluation of biochemical parameters 
Jaffe’s method was used for the evaluation of creatinine, 
diacetylmonoxime method was used for the evaluation 
of urea while uric acid was evaluated using 
phosphotungstic acid method [15].  Albumin was 
determined using end point method while total protein 
level was assayed using Biuret method [16]. The method 
of Reitman and Frankel (1957) [17] was used for the 
evaluation of aspartate transaminase and alanine 
transaminase. Alkaline phosphatase was assayed using 
phenolphthalein method [18]. Kidney Superoxide 
dismutase activity was determined according to Sun and 
Zigma [19] while catalase activity was determined 
according to Sinha, et al. [20]. Reduced glutathione 
(GSH) was estimated as reported by Sedlak and Lindsay 
[21] while glutathione peroxidase was analyzed as 
reported by Rotruck et al. [22]. Malondialdehyde 
(MDA)was determined as described by Buege and Aust 
[23]. Flame photometric methods were used for the 
evaluation of potassium and sodium while titrimetric 
method was used for chloride analysis. Bicarbonate level 
was evaluated using standard laboratory test kits. 
Histological examination of the kidney 
Kidney tissues were collected from different groups and 
were fixed in 10% buffered formalin solution. The 
tissues were processed, embedded in paraffin and 
sections of 5µm thickness were obtained. The sections 
were stained with hematoxylin and eosin and examined 
using a light microscope. 
Statistical analysis 
Data are represented as means ± SD. The differences 
were compared for statistical significance by ANOVA 
and Tukey’s post-hoc test. Difference was considered 
significant at p < 0.05. 
Results 
Body weight, absolute and relative kidney weights and 
serum electrolytes (K+, Na+, Cl- and HCO3-) were not 
significantly (p>0.05) altered in TD-DF treated rats 
when compared to control (Table 1 and3). On the other 
hand, serum Cr, U and UA were significantly (p<0.05) 
increased in TD-DF treated rats when compared to 
treatments with individual doses of TD and DF (Table 
3). Furthermore, serum levels of TP and Ab were 
decrease in TD-DF treated rats. The observed decreases 
in serum TP and Ab levels were significantly (p<0.05) 
different when compared to treatments with individual 
doses of TD and DF (Table 3). Furthermore, in the TD-
DF treated rats, MDA levels were increased while SOD, 
CAT and GSH levels were decreased. Comparatively, 
effects on these parameters differ significantly (p<0.05) 
in comparison to effects produced by their individual 
doses (Table 4). The kidney levels of AST, ALT and ALP 
were increased by 120.3%, 106.1% and 125.7% 
respectively in TD-treated rats.  
These parameters were increased by 111.1%, 100.5% 
and 131.1 % in DF-treated rats while 278.5%, 304.7% 
and 350.8 % increases were obtained in TD-DF treated 
rats respectively.  
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Groups 
 
Initial body 
Weight (g) 
Final body 
weight  (g) 
Change in 
bodyweight (%) 
Absolute kidney 
weight (g) 
Relative kidney 
weight (%) 
A (placebo)   240 ± 10.4   258 ± 12.0    18 1.21 ± 0.26 0.53 ± 0.07 
B (solvent)    268 ± 12.1   288 ± 10.9    20 1.18 ± 0.13 0.48± 0.02 
C    229 ± 11.6   246 ± 13.2    17 1.20 ± 0.42 0.55 ± 0.07 
D   254 ± 10.8   273 ± 14.6    19 1.15 ± 0.69 0.48 ± 0.05 
E   233 ± 13.4   253 ± 10.9    20 1.08 ± 0.31 0.47 ± 0.03 
F   257 ± 13.6   275 ± 13.1    18 1.20 ± 0.83 0.49 ± 0.02 
G   246 ± 10.7   265 ± 15.6    19 1.28 ± 0.47 0.53 ± 0.01 
n=6. Values are expressed as mean ± SD. F= Recovery group allowed for a wash-out period of 7days. G= Recovery group allowed for a wash-
out period of 14 days 
Table 1: Effects of tramadol and diclofenac treatment on body and kidney weights albino rats 
Drug 
 
Urea 
mg/dL 
Creatinine 
mg/dL 
uric acid 
mg/dL 
total protein 
g/dL 
Albumin 
g/dL 
A (placebo) 33.1 ± 0.80a 1.37 ± 0.19a 1.25 ± 0.81a 8.01 ± 0.43a 4.29 ± 0.51a 
B (solvent) 32.1 ± 0.75 a 1.28 ± 0.36a 1.20 ± 0.54a 8.10 ± 0.75a 4.35 ± 0.73a 
C 61.1 ± 2.27b 2.89 ± 0.49b 2.94 ± 0.77b 5.85 ± 0.30b 2.37 ± 0.12b 
D 57.7 ± 2.55b 2.78 ± 0.55b 2.73 ± 0.54b 5.69 ± 0.32b 2. 20 ± 0.75b 
E 136.1 ± 5.74c 5.85 ± 0.26c 5.84 ± 0.13c 2.08 ± 0.76c  1.14 ± 0.22c 
F 85.0 ± 7.25b 3.27 ± 0.63b 3.40 ± 0.56d 5.25 ± 0.65d 3.51 ± 0.38d 
G 55.7± 5.00e 2.17 ± 0.43e 1.35 ± 0.49a 7.85 ± 0.15a 4.21 ± 0.78a 
n=6. Values are expressed as mean ± SD. F= Recovery group allowed for a wash-out period of 7days. G= Recovery group allowed for a wash-
out period of 14 days. Values with different superscripts down the column differ significantly at p<0.05 ANOVA 
Table 2: Effects of tramadol and diclofenac on serum renal function parameters of albino rats 
Groups 
 
MDA 
nmole/mg/protein 
GSH 
µg/ mg protein 
CAT 
U/mg protein 
SOD 
U/mg protein 
GPX 
U/mg protein 
A (placebo) 0.26 ± 0.02a 8.27 ± 0.43a 30.5 ± 3.11a 18.5 ± 2.20a 22.5 ± 2.99a 
B (solvent) 0.24 ± 0.09a 8.30 ± 0.75a 31.0 ± 4.32a 20.1 ± 2.09a 25.5 ± 3.10a 
  C 0.49 ± 0.03b 4.83 ± 0.24b 20.5 ± 2.61b 10.8 ± 1.39b 15.8 ± 1.39b 
  D 0.46 ± 0.02b 4.63 ± 0.08b 18.6 ± 3.34b 10.3 ± 1.43b 13.9 ± 1.43b 
  E 0.95 ± 0.02c 1.30 ± 0.11c 5.20 ± 0.12c 4.21 ± 0.54c 6.21 ± 0.54c 
  F 0.50 ± 0.06d 3.42 ± 0.41d 15.8 ± 2.82d 7.94 ± 1.27d 9.74 ± 1.27d 
  G 0.28 ± 0.04a 6.21 ± 0.79e 29.8 ± 2.82a 13.1 ± 1.27e 21.9 ± 3.11a 
n=6. Values are expressed as mean ± SD. F= Recovery group allowed for a wash-out period of 7days. G= Recovery group allowed for a wash-
out period of 14 days. Values with different superscripts down the column differ significantly at p<0.05 ANOVA 
Table 3: Effects of tramadol and diclofenac on kidney oxidative stress indices of albino rats 
    Groups AST(U/L) ALT(U/L) ALP (U/L) 
  A (placebo) 129.7 ± 11.9a 130.6 ± 10.0a 110.6 ± 12.1a 
  B (solvent) 134.1 ± 13.8a 126.2 ± 12.8a 110.6 ± 13.7a 
  C 285.7 ± 15.1b 269.1 ± 10.7b 249.0 ± 11.3b 
  D 270.3 ± 14.4b 261.9 ± 14.6b 255.6 ± 14.8b 
  E 490.6 ± 13.5c 528.5 ± 13.9c 498.6 ± 13.3c 
  F 285.1 ± 12.7d 235.3 ± 14.3d 270.6± 12.6d 
  G 160.2 ± 10.7a 155.6± 11.5a 130.7 ± 10.1a 
n=6. Values are expressed as mean ± SD. F= Recovery group allowed for a wash-out period of 7days. G= Recovery group allowed for a wash-
out period of 14 days. Values with different superscripts down the column differ significantly at p<0.05 ANOVA 
Table 4: Effects of tramadol and diclofenac on kidney aminotransferases and alkaline phosphatase of albino rats 
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Group 
 
Sodium 
mEq/L 
Potassium 
mEq/L 
Chloride 
mEq/L 
Bicarbonate 
mmol/dL 
A (placebo) 134.1 ± 12.1 4.26 ± 0.14 111.6 ± 13.1 17.9 ± 0.37 
B (solvent) 130.6 ± 12.6 4.25 ± 0.65 114.1 ± 10.1 16.2 ± 0.56 
C 131.7 ± 14.3 4.22 ± 0.23 107.5 ± 10.3 18.4± 0.60 
D 122.0 ± 11.4 4.21 ± 0.40 110.0 ± 11.5 20.1 ± 0.69 
E 127.1 ± 13.5 4.17 ± 0.34 106.4 ± 14.7 16.3 ± 0.44 
F 130.5 ± 12.7 4.20 ± 0.21 109.7 ± 12.1 20.2 ± 0.83 
G 132.6 ± 14.7 4.28 ± 0.17 105.6 ± 11.1 18.7 ± 0.61 
n=6. Values are expressed as mean ± SD. F= Recovery group allowed for a wash-out period of 7days. G= Recovery group allowed for a wash-
out period of 14 days. 
Table 5: Effects of tramadol and diclofenac treatment on serum electrolytes of albino rats 
  
  
  
Fig A:  Kidney of control rat showing normal histology. Fig B: Kidney of rat treated with 12 mg/kg/day of tramadol hydrochloride for 14 days 
showing dilated tubules and necrosis of tubular   epithelium. Fig C: Kidney of rat treated with 6 mg/kg/day of diclofenac potassium for 14 days 
showing dilated tubules and necrosis of tubular epithelium. Fig D: Kidney of rat treated with 12 mg/kg/day of tramadol hydrochloride and 6 
mg/kg/day of diclofenac potassium for 14 days showing dilated tubules, necrosis of tubular epithelium and eosinophylic materials in the 
tubular lumen. Fig E: Kidney of rat treated with 12 mg/kg/day of tramadol hydrochloride and 6 mg/kg/day of diclofenac potassium for 14 days 
and allowed to recover for 7 days showing tubular necrosis. Figure F:  Kidney of rat treated with 12 mg/kg/day of tramadol hydrochloride and 
6 mg/kg/day of diclofenac potassium for 14 days and allowed to recover for 14 days showing normal histology (Hand E X200) 
A          B 
C          D 
E          F 
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The increases observed in AST, ALT and AST in rats 
treated with TD-DF differ significantly (p<0.05) when 
compared to individual doses of TD and DF (Table 5). 
However, the altered levels of evaluated parameters in 
TD-DF treated rats were significantly (p<0.05) restored 
in the recovery groups allowed for a wash-out period of 
7 and 14 days respectively when compared to TD-DF 
treated rats.   In addition, the kidney of the control rat 
administered with water showed normal histology 
(Figure A). The kidneys of rats treated with TD showed 
dilated tubules and necrosis of tubular epithelium, also, 
the kidneys of DF treated rats showed dilated tubules 
and necrosis of tubular epithelium. Furthermore, the 
kidneys of TD-DF treated rats showed dilated tubules, 
necrosis of tubular epithelium and eosinophylic 
materials in the tubular lumen. The kidneys of the 
recovery group allowed for a wash-out period of 7 days 
showed tubular necrosis while the recovery group 
allowed for a wash-out period of 14 days showed normal 
kidney histology (Figure B-F). 
Discussion  
Body and organ weights are key indices for the 
toxicological assessments of drugs because they could be 
modified with the advent of drug-induced toxicity [24]. 
In the present study, body weight, absolute and relative 
kidney weights were not altered in TD-DF treated rats. 
Serum biochemical markers are integral component and 
tools used for the assessments of the toxicological profile 
of xenobiotics. Serum electrolytes are essential renal 
biochemical markers. They are associated with vital 
functions which include the maintenance of acid–base 
balance, osmotic pressure, movement and regulation of 
fluids and muscular activity. Renal toxicity associated 
with drugs can be characterized by serum electrolyte 
fluctuations which could be detrimental to health 
[25,26]. This study observed normal levels of serum 
electrolytes in TD-DF treated rats. In clinical practice, 
serum creatinine level is widely used to estimate 
glomerular filtration rate and it serves as an index for 
renal function assessment [27]. Urea which is a 
nitrogenous waste is produce from the metabolism of 
protein and amino acid and is primarily eliminated 
through urinary excretion. It is an essential clinical 
parameter for the assessment of the nephrotoxic profile 
of xenobiotics. Uric acid is the product of the oxidation 
of purine which it is excreted through the urine [28]. The 
assessments of creatinine, urea, and uric acid levels can 
be correlated with the functional status of the kidney 
[29,30]. The observations in the current study showed 
increased serum levels of creatinine, urea, and uric acid 
in TD-DF treated rats. This finding is a sign of renal 
toxicity which might have instigated decrease in 
glomerular filtration rate leading to the build-up of 
creatinine, urea and uric acid in the blood. Clinical 
diagnosis have shown that decreases in serum 
concentrations of protein and albumin characterized by 
significant increases in the urinary excretion of protein 
and albumin are indicators of renal dysfunction [30].. 
The observations in this study showed decreases in the 
serum concentration of total protein and albumin in 
TD-DF treated rats which indicate kidney damage. 
Furthermore, kidney levels of AST, ALT and ALP were 
increased in TD-DF treated rats in comparison to 
treatment with individual doses TD and DF. Superoxide 
dismutase(SOD) catalytically convert super oxide anion 
to oxygen  and hydrogen peroxide [31] while catalase 
(CAT) inhibits cell damage by degrading hydrogen 
peroxide to water and oxygen [32]. Glutathione (GSH) 
contains thiol group stored as cysteine residue, it acts by 
inhibiting activities of reactive oxygen/nitrogen species 
and electrophiles and as a cofactor for enzymes [33,34]. 
Glutathione peroxidase (GPx) is a selenoenzyme that 
facilitates the activity of glutathione through the 
reduction of harmful peroxides. Also, it actively protects 
lipid membranes and other cellular components from 
harmful effect of oxygen/nitrogen species [35]. Due to 
the modulatory effects of SOD, CAT, GSH and GPX on 
oxidative processes, their concentrations are often 
correlated with oxidative stress [36,37]. The kidney 
levels of SOD, CAT, GSH and GPX were decreased in 
the TD-DF treated rats. The observation could be as a 
result of the induction of oxidative stress by TD-DF 
through the production of oxidative radicals in the 
kidneys of treated rats. Lipid peroxidation is a free 
radical reaction, stimulated by the interaction of 
oxidative radicals with unsaturated lipids present in bio-
membranes. This will result in the production of lipid 
hydro peroxide, lipid peroxide radicals, and products 
such as malondialdehyde (MDA). Studies use MDA as a 
basic biological tool for the assessment of lipid 
peroxidation and its concentration is usually high when 
oxidative stress is established [38]. The current study 
observed elevated level of MDA in TD-DF treated rats. 
This showed that nephrotoxicity due to TD-DF could be 
associated with lipid peroxidation. Conventional 
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histological stains such as haematoxylin and eosin are 
commonly used for the preparation of tissues for 
histological evaluation [39]. Histological assessment of 
the haematoxylin and eosin stained sections of the 
kidneys of rats treated with TD-DF showed varying 
degrees of architectural distortions. This observation 
could be attributed to the induction of oxidative stress 
and lipid peroxidation through oxidative radical 
generation by TD-DF. Empirical evidence has shown 
that the production of oxidative radicals in biological 
systems primarily hydroxyl radicals, peroxy radicals and 
superoxide anion can damage bio-membranes and 
biomolecules like lipids, amino acids and nucleic acids. 
Also, free radicals can denature proteins in kidneys 
leading to aggregation, loss of function, cross-linking, 
and destruction of connective tissues [40]. However, the 
most destructive effect of oxidative radicals is the 
induction of lipid peroxidation through the breakdown 
of poly-unsaturated fatty acid component of cells [41]. 
In this study, the altered levels of evaluated biochemical 
parameters correlate with histopathological damage 
observed in the kidneys of TD-DF treated rats. It is of 
interest to note that renal toxicity observed in TD-DF 
treated rats were reversed in the recovery groups. 
However, recovery was more prominent in the 14 days 
recovery group. These findings showed that renal 
toxicity associated with the use of TD-DF could reverse 
with time.  
Furthermore, in this study, observations in the TD-
treated rats are consistent with the work of Alkhateeb et 
al. who reported elevated levels of creatinine and urea 
and tubular necrosis in the kidneys of rats treated with 
30mg/kg of TD for 30 days [42]. Abdel-Zaher et al. 
reported altered levels of oxidative stress biomarkers in 
TD-treated mice [43]. Renal insufficiency due to the 
decreased glomerular filtration rate characterized by 
increase oxidative radical production was reported as 
possible cause of TD-induced nephrotoxicity [44]. Also, 
observations in DF-treated rats are consistent with the 
work of Yasmeen et al. who reported increases in 
creatinine, urea and uric acid and tubular necrosis in 
rats administered with 2mg/kg/day of DF for 14 days 
[45]. Also, Basavraj et al observed increases in serum 
creatinine and urea with decreases in total protein and 
albumin in mice- treated orally with 9.5 mg/kg/day of 
DF for 28 days [46]. In addition, El-Maddawy et al. 
reported altered levels of oxidative stress indices in the 
kidneys of rats administered with 13.5 mg / kg/day of DF 
intramuscularly for 14 day [47].  
Studies have attributed the nephrotoxic effect of DF to 
the inhibition of renal prostaglandin synthesis, which 
influences cortical blood flow, glomerular filtration rate 
and salt and water excretion [48]. The use of tramadol-
diclofenac could be associated with reversible 
nephrotoxicity. The present study recommends renal 
function assessment before use. 
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